Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/10.SUPPL_2.S23PMID 10399029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RADlATlON SPECTRA FOR AUGER-ELECTRON EMITTING RADIONUCLIDES

  2000cited by this paper
• Somatostatin Receptor Scintigraphy

  1999cited by this paper
• Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.

  1998cited by this paper
• Yttrium-90-labelled somatostatin-analogue for cancer treatment.

  1998cited by this paper
• Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

  1997cited by this paper
• Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management.

  1997cited by this paper
• DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

  1997cited by this paper
• Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.

  1997influential reference
• D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.

  1997cited by this paper
• Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.

  1996cited by this paper
• Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study

  1996cited by this paper
• Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.

  1996cited by this paper
• Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.

  1996cited by this paper
• Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.

  1996cited by this paper
• In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P.

  1996cited by this paper
• Somatostatin receptor: scintigraphy and radionuclide therapy.

  1996cited by this paper
• Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

  1994cited by this paper
• Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐Octreotide

  1994cited by this paper
• Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.

  1994cited by this paper
• Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.

  1994cited by this paper
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  1993cited by this paper
• Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype.

  1993cited by this paper
• Merrill C. Sosman Lecture. The Auger process: a therapeutic promise?

  1993cited by this paper
• Somatostatin receptors: orphan that found family and function.

  1993cited by this paper
• Cloning and characterization of a fourth human somatostatin receptor.

  1993cited by this paper
• Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6.

  1992cited by this paper
• Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

  1992cited by this paper
• [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.

  1991cited by this paper
• Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line.

  1982cited by this paper
• Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids.

  1977cited by this paper

• Contemporary opportunities and potential of Auger electron-emitting theranostics

  2026cites this paper
• Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma

  2025influential citation
• Prognosis of NETs: Has There Been Improvement over the Last 30 Years?

  2025cites this paper
• [18F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paraganglia

  2025cites this paper
• Comparison of quantitative Krenning Scores with visual assessment in 99mTc-EDDA/HYNIC-TOC SPECT-CT

  2025cites this paper
• Radioligand therapies in meningioma: Evidence and future directions

  2024cites this paper
• PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences

  2024cites this paper
• Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors

  2024cites this paper
• Advances in Radioligand Theranostics in Oncology

  2024cites this paper
• The University of Iowa Neuroendocrine Tumor Clinic.

  2024cites this paper
• Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

  2024cites this paper
• Somatostatin Radioligand Therapy of Breast Cancer: A Target of Opportunity.

  2024cites this paper
• Multimodal management of foregut neuroendocrine neoplasms.

  2024cites this paper
• PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview

  2024cites this paper
• Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors

  2024cites this paper
• Combination Strategies and Targeted Radionuclide Therapies.

  2024cites this paper
• Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours

  2024cites this paper
• Neuroendocrine Tumor Therapy Response Assessment.

  2023cites this paper
• A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.

  2023cites this paper
• Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE

  2023cites this paper
• 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic

  2023cites this paper
• The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)

  2023cites this paper
• Nature-inspired and medicinally relevant short peptides

  2023cites this paper
• Sequencing of Therapies in Progressive Neuroendocrine Tumors

  2022cites this paper
• Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues

  2022cites this paper
• Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy

  2022cites this paper
• Towards accurate partial volume correction in 99mTc oncology SPECT: perturbation for case-specific resolution estimation

  2022cites this paper
• Radioligand therapy — personalized treatment for patients with neuroendocrine tumors

  2022cites this paper
• Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC

  2022cites this paper
• Amino Acid Solutions for 177Lu-Oxodotreotide Premedication: A Tolerance Study

  2022cites this paper
• Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea

  2022cites this paper
• Radionuclides for Targeted Therapy: Physical Properties

  2022cites this paper
• Auger: The future of precision medicine.

  2021cites this paper
• Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

  2021cites this paper
• Intra-arterial Radiopeptide Infusions with High Activity of 111In-Octreotide: From “Aretaieion Protocol” to the Temporal Intra-arterial Port Installation

  2021cites this paper
• Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

  2021cites this paper
• Therapiekonzepte beim Schilddrüsenkarzinom

  2021cites this paper
• Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma

  2021cites this paper
• Development of a new quantification method using partial volume effect correction for individual energy peaks in 111In-pentetreotide SPECT/CT

  2021cites this paper
• Intravenous Radiopeptide Infusions with High Activity of 111In-Octreotide

  2021cites this paper
• Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review

  2021cites this paper
• Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma

  2021cites this paper
• Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead

  2021cites this paper
• Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management

  2021cites this paper
• Treatment of NET-Related Symptoms

  2021cites this paper
• Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

  2021cites this paper
• Theranostics in Thyroid Cancer.

  2021cites this paper
• Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.

  2021cites this paper
• Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

  2021cites this paper
• Therapiekonzepte beim Schilddrüsenkarzinom

  2021cites this paper
• Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities

  2020cites this paper
• Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma

  2020cites this paper
• Somatostatin receptor targeted radioligand therapy in head and neck paraganglioma.

  2020cites this paper
• PRRT: identikit of the perfect patient

  2020cites this paper
• Auger electrons for cancer therapy – a review

  2019cites this paper
• Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary Sjögren Syndrome

  2019cites this paper
• Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

  2019cites this paper
• Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

  2019cites this paper
• 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases)

  2019cites this paper
• Physiopathological premises to Nuclear Medicine Imaging of pancreatic neuroendocrine tumours.

  2019cites this paper
• Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.

  2018cites this paper
• Synthesis and Anticancer Screening of Combinatorial Libraries of Cyclic Peptides and Other Compounds

  2018cites this paper
• 177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience

  2018cites this paper
• Lung and Thymic Carcinoids.

  2018cites this paper
• Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.

  2018cites this paper
• Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

  2018cites this paper
• Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's Syndrome

  2017cites this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cites this paper
• Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.

  2017cites this paper
• Somatostatin analogues labeled with copper radioisotopes: current status

  2017cites this paper
• Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?

  2017cites this paper
• New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification

  2017cites this paper
• Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas)

  2017cites this paper
• Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy

  2017cites this paper
• The role of patient-based treatment planning in peptide receptor radionuclide therapy

  2016cites this paper
• 68Ga‐DOTA‐peptide: A novel molecular biomarker for nasopharyngeal carcinoma

  2016cites this paper
• Chapter 151 – Carcinoid Syndrome

  2016cites this paper
• Chapter 46 – Uncommon Thoracic Tumors

  2016cites this paper
• Peptide Receptor Radionuclide Therapy (PRRT)

  2016cites this paper
• Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.

  2016cites this paper
• Tumores neuroendocrinos gastroenteropancreáticos Nuevos tratamientos en los tumores neuroendocrinos gastroenteropancreáticos

  2016cites this paper
• Somatostatin Receptor Based Imaging and Radionuclide Therapy

  2015cites this paper
• Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

  2015cites this paper
• Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review

  2015cites this paper
• Peptide Receptor Radionuclide Therapy: An Overview

  2015cites this paper
• Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT

  2014cites this paper
• Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors: The First US Phase 2 Experience

  2014cites this paper
• Biomarker discovery and assessment for prediction of kidney response after 177Lu-octreotate therapy

  2014cites this paper
• Somatostatin Receptor Imaging in Non–131I-Avid Metastatic Differentiated Thyroid Carcinoma for Determining the Feasibility of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE: Low Fraction of Patients Suitable for Peptide Receptor Radionuclide Therapy and Evidence of Chromogranin A Level–Po

  2014cites this paper
• Pharmacokinetics, dosimetry and kidney toxicity

  2014cites this paper
• Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy.

  2013cites this paper
• Dosimetric Analyses of Kidneys, Liver, Spleen, Pituitary Gland, and Neuroendocrine Tumors of Patients Treated With 177Lu-DOTATATE

  2013cites this paper
• Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

  2013cites this paper
• Peptide imaging with somatostatin analogues: more than cancer probes.

  2013cites this paper
• Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives

  2013cites this paper
• Neuroendocrine tumours: cracking the epigenetic code.

  2013cites this paper
• Radionuclide Therapy of Neuroendocrine Tumors

  2013cites this paper
• Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.

  2012cites this paper
• Cancer Treatment Using Peptides: Current Therapies and Future Prospects

  2012cites this paper
• Treatment options for unresectable neuroendocrine liver metastases

  2012cites this paper